Ozempic pill? Trial suggests new oral drug works as well as injectables for type 2 diabetes
An experimental pill may work just as well as injectable, Ozempic-style drugs at treating type 2 diabetes, early trial results suggest.
The oral medication, called orforglipron, belongs to a class of drugs called glucagon-like peptide 1 (GLP-1) agonists. This class also includes Ozempic, which is made by Novo Nordisk and approved as a blood-sugar control aid in type 2 diabetes, as well as a treatment for people with type 2 and either heart disease or kidney disease. It also includes Wegovy, which has the same active ingredient as Ozempic but is approved for chronic weight management.
GLP-1 agonists are best known as weight-loss drugs, and likely drive weight loss in part by slowing digestion and curbing appetite by messing with hunger signals in the body. In diabetes, the drugs help lower blood sugar by boosting levels of insulin, the hormone responsible for shuttling sugar out of the blood.
However, as of yet, GLP-1s are all injectable medications that require refrigeration, The New York Times reported. It's possible that introducing a daily pill that can achieve the same results could potentially increase the availability and use of the medications, Lilly, the drug's maker, suggests.
Related: Ozempic-style drugs tied to more than 60 health benefits and risks in biggest study-of-its-kind
"Injections cannot be the solution for billions of people around the world," Dr. Daniel Skovronsky, chief scientific officer of Lilly, told The New York Times.
In a statement published Thursday (April 17), Lilly shared the topline results of a late-stage trial of orforglipron. The trial's results have not yet been published in a scientific journal but will be in the future, and the results will also be presented at the American Diabetes Association's 85th Scientific Sessions, the statement noted.
The trial included 559 adults with type 2 diabetes whose blood sugar was not adequately controlled with diet and exercise alone. For just over nine months, the participants took either orforglipron or a placebo pill daily. Those taking orforglipron got one of three doses: 3 milligrams, 12 mg or 36 mg.
After 40 weeks, the trial runners checked everyone's blood sugar levels using an A1C test, which can reveal average blood-sugar levels from the preceding three months. The test gives results as a percentage, with 6.5% or higher typically indicating diabetes and 5.7% to 6.4% signaling prediabetes. The participants in the trial started out with an average A1C of 8%.
After 40 weeks, the groups who took orforglipron saw their A1C drop by 1.3% to 1.6%, on average, while the placebo fell only 0.1%. That effect is about the same as what was seen in separate trials of Ozempic and Mounjaro, another GLP-1, The New York Times reported.
Around two-thirds of those who took the highest dose of the drug had their levels fall to less than or equal to 6.5%, the threshold for diabetes. The high-dose group also lost an average of 16 pounds (7.3 kilograms) each. The other dosing groups lost about 10 to 12 pounds (4.4 to 5.5. kg), while the placebo group lost about 3 pounds (1.3 kg).
"Given that participants had not yet reached a weight plateau at the time the study ended, it appears that full weight reduction was not yet attained," the Lilly statement noted.
RELATED STORIES
—$3 million Breakthrough Prize awarded to developers of Ozempic-style drugs
—Ozempic-like meds linked to higher risk of pancreatitis, 'stomach paralysis' than other weight-loss drugs
—Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs
The most common side effects were mild to moderate and were similar to those seen with other GLP-1s. For example, diarrhea, nausea, indigestion, constipation and vomiting were more common in the treatment groups than the placebo. Between 3% and 8% of the participants in each treatment group opted to stop taking the medication, compared to 1% of the placebo.
Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes, The New York Times reported. In addition to the diabetes trial described above, the company is also testing the pill in adults with obesity or who are overweight with at least one weight-related medical problem. They're also investigating its use as a treatment for high blood pressure and sleep apnea in people with obesity.
The price of the pill has not yet been announced.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
6 minutes ago
- CBS News
An area of Lake Tahoe has elevated levels of E. coli, testing revealed
An area of Lake Tahoe tested for high levels of E. coli, prompting a warning to stay out of the water, the U.S. Forest Service said on Friday. The tested samples were from the South Shore of Lake Tahoe near Camp Richardson Resort. Due to the elevated levels of E. coli, the Forest Service said people should not swim in the area between Jameson Beach and the Valhalla Boathouse. Those two areas were tested and did not show elevated levels of E. coli as of Friday. After elevated levels of E. coli were found, the resort immediately inspected its sewer lines, the Forest Service said. A leak was found, and repairs are underway. The elevated levels were found because agencies in Lake Tahoe routinely test the water during the summer to make sure it's safe for recreation, the Forest Service said. Officials will test the area daily to let people know when it's safe to return. They could also implement more precautions depending on E. coli levels. E. coli can cause diarrhea, stomach cramps, vomiting and fever. The Centers for Disease Control and Prevention advises people not to swallow water when swimming or playing in recreational waters such as lakes, ponds, rivers, streams and swimming pools.
Wall Street Journal
20 minutes ago
- Wall Street Journal
Best Pet Insurance Companies of 2025
Factors in pet insurance costs Factors that influence how much you'll pay for pet insurance usually include: Age and breed of the pet Where you live Annual coverage limit Reimbursement level Amount of your deductible Any additional coverage you want, such as add-ons or a wellness plan You can generally lower the price of a pet insurance policy by choosing a lower annual coverage limit, a higher deductible or a lower reimbursement percentage. When you get a pet insurance quote, you can usually toggle the options to see how the monthly price changes. Is pet insurance worth it? While paying a monthly premium for pet insurance can feel like a drain on the budget, the risk of higher costs for procedures and chronic conditions might be more than you can afford without insurance. The ASPCA estimates that the first-year total for owning a dog is more than $3,000 and almost $2,000 for a cat. Once you get past the first year, though, there are ongoing costs, including routine medical costs and treatments for fleas and ticks, as well as heartworm. You have routine wellness visits and exams as well. Like other insurance policies, the biggest value comes in the event of large, unexpected emergencies. EmergencyVetsUSA offers these average cost examples: Emergency exam/consultation: $100 to $150 $100 to $150 3- to 5-day hospitalization: $1,500 to $3,500 $1,500 to $3,500 Emergency surgery: $1,500 to $5,000 $1,500 to $5,000 Wound treatment and repair: $800 to $2,500 Additionally, if your pet needs special prescription pet food or supplements, the cost can add up over time. Getting a pet insurance policy that covers these ongoing costs, plus emergency situations, can help you save money in the long run, especially if you don't want to deplete your rainy day fund. What's not covered by pet insurance? What's covered depends on the policy, so review available benefits before deciding on a pet insurance company. Policies typically do not cover pre-existing conditions or non-veterinary expenses related to boarding your pet or grooming. You also won't receive reimbursement for accessories like toys, leashes and treats. Basic wellness, such as vaccinations and routine check-ups, won't be covered. Instead, you'll need to purchase an add-on wellness plan to receive these benefits. Many first-year costs, such as spaying and neutering, also aren't usually covered by base pet insurance policies but may be covered by a wellness plan. Costs related to breeding are generally not covered, and injuries related to activities like racing aren't covered. Methodology We evaluated 15 pet insurance policies, focusing on key coverage areas, such as cost, access to vet telehealth, microchipping, direct vet payments and therapies that pet owners might prefer to be included in coverage. Advertisers and partners don't influence our ratings, as our research and editorial team maintains independence in using data-driven methodologies. Learn more about how Buy Side rates pet insurance companies.
CBS News
36 minutes ago
- CBS News
Menopause retreat helps new generation of women find relief and cope with stigmas: "We're suffering silently and that's not OK"
Monica Conn, 53, describes menopause as "hot flashes, anxiety, night sweats, irritability." Instead of continuing to suffer silently through the brutal hormonal transition that 47 million women experience annually around the world, Conn has decided to do—and say—something about it. "I want to take away an attitude that I'm looking forward to my next chapter and not that something has just ended," Conn said. She signed up for the Canyon Ranch Health Spa's M/Power program, a four-day holistic menopause retreat in the Massachusetts Berkshires that promises relief, education and counseling. The Centers for Disease Control and Prevention defines menopause as "when menstrual periods stop permanently for at least 12 months," and common symptoms echo Conn's description: hot flashes, trouble sleeping, mood swings and memory problems, to name a few. M/Power's menopause and perimenopause retreats offer respite and resolve from symptoms through activities like yoga, weight training, cold plunges and more. For a long time, women have been suffering in silence about the impact symptoms have on their daily lives. "I'm learning here at Canyon Ranch that I don't know how much training our doctors even get," Conn said, adding, "the mental health component of it, how to address that, how healthy, basic foods can help you get through the day and how they affect your metabolism and your anxiety." Another aspect of the M/Power retreat is medical diagnosis, which includes blood work, hormone panels, and a DEXA body scan, which can assess things like fat composition and bone density. Dr. Jennifer Baker-Porazinski explained that a lack of estrogen, which plummets in women during menopause, causes bone density to drop—putting them at higher risk for broken bones. She says that women lose around 2% of their bone density each year for around 10 to 12 years after starting menopause. Another option for women hoping to curb symptoms is hormone therapy (HRT) but some fear it because of preliminary findings that connected HRT to increased risk of breast cancer, though critics later found flaws in the research. "Hormone therapy is the most effective treatment for the symptoms of menopause," said Dr. Sharon Malone, chief medical advisor for the women's telehealth platform "Alloy" and author of "Grown Woman Talk." Most doctors recommend taking hormones before turning 60, or within 10 years of starting menopause. For former TV journalist Tamsen Fadal, managing menopause is about community. She said she began experiencing her symptoms live on-air, and felt isolated, so she wrote the book "How to Menopause." It is essentially a "how-to" guide for women beginning the process of perimenopause or menopause. "I think this Gen X really kinda kicked the door down and said, 'hey, we're suffering silently and that's not OK.' There has to be some type of solution," Fadal said.
